In our previous study in simvastatin on endometrial cancer, we found that treatment with simvastatin resulted in inhibition of the MAPK pathway and exhibited differential effects on the AKT/mTOR pathway in the ECC-1 and Ishikawa cells [35]. The gene discussed is AKT1; the disease is endometrial cancer.